CoMFA and CoMSIA studies on C-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents

SGLT2 has become a target of therapeutic interest in diabetes research. CoMFA and CoMSIA studies were performed on C-aryl glucoside SGLT2 inhibitors (180 analogues) as potential anti-diabetic agents. Three different alignment strategies were used for the compounds. The best CoMFA and CoMSIA models were obtained by means of Distill rigid body alignment of training and test sets, and found statistically significant with cross-validated coefficients (q 2) of 0.602 and 0.618, respectively, and conventional coefficients (r 2) of 0.905 and 0.902, respectively. Both models were validated by a test set of 36 compounds giving satisfactory predicted correlation coefficients (r 2 pred) of 0.622 and 0.584 for CoMFA and CoMSIA models, respectively. A comparison was made with earlier 3D QSAR study on SGLT2 inhibitors, which shows that our 3D QSAR models are better than earlier models to predict good inhibitory activity. CoMFA and CoMSIA models generated in this work can provide useful information to design new compounds and helped in prediction of activity prior to synthesis.

[1]  A. Dixit,et al.  Development of CoMFA, advance CoMFA and CoMSIA models in pyrroloquinazolines as thrombin receptor antagonist. , 2004, Bioorganic & medicinal chemistry.

[2]  Min Ju Kim,et al.  Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors. , 2011, Bioorganic & Medicinal Chemistry Letters.

[3]  Min Ju Kim,et al.  Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 Inhibitors. , 2011, ACS medicinal chemistry letters.

[4]  Li Xin,et al.  Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats , 2008, Diabetes.

[5]  W. Humphreys,et al.  Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. , 2008, Journal of medicinal chemistry.

[6]  B. Goldstein,et al.  Sodium glucose co‐transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes , 2008, International journal of clinical practice.

[7]  Chari D Smith,et al.  Synthesis and SAR of Benzisothiazole- and Indolizine-β-d-glucopyranoside Inhibitors of SGLT2. , 2010, ACS medicinal chemistry letters.

[8]  J. Sridhar,et al.  QSAR models of cytochrome P450 enzyme 1A2 inhibitors using CoMFA, CoMSIA and HQSAR , 2011, SAR and QSAR in environmental research.

[9]  Yoshikazu Fujimori,et al.  Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level , 2007, Journal of Pharmacology and Experimental Therapeutics.

[10]  V. Fonseca,et al.  Turning Glucosuria into a Therapy: Efficacy and Safety with SGLT2 Inhibitors , 2010, Current diabetes reports.

[11]  Amit K. Gupta,et al.  3D-QSAR CoMFA and CoMSIA studies on a set of diverse α1a-adrenergic receptor antagonists , 2011, Medicinal Chemistry Research.

[12]  Gyanendra Pandey,et al.  3D QSAR Studies on Protein Tyrosine Phosphatase 1B Inhibitors: Comparison of the Quality and Predictivity among 3D QSAR Models Obtained from Different Conformer-Based Alignments , 2006, J. Chem. Inf. Model..

[13]  Jong Yup Kim,et al.  Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[14]  J. Wanga,et al.  Receptor-based QSAR study for a series of 3 , 3-disubstituted-5-aryl oxindoles and 6-aryl benzimidazol-2-ones derivatives as progesterone receptor inhibitors , 2011 .

[15]  H. Bhatt,et al.  Pharmacophore modeling, virtual screening and 3D-QSAR studies of 5-tetrahydroquinolinylidine aminoguanidine derivatives as sodium hydrogen exchanger inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[16]  S Wold,et al.  Multivariate data analysis and experimental design in biomedical research. , 1988, Progress in medicinal chemistry.

[17]  Rury R. Holman,et al.  Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) , 1999 .

[18]  W. Humphreys,et al.  Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2. , 2008, Bioorganic & medicinal chemistry letters.

[19]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[20]  E. Wright,et al.  The sodium/glucose cotransport family SLC5 , 2003, Pflügers Archiv.

[21]  Jinhwa Lee,et al.  Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors. , 2010, Bioorganic & medicinal chemistry.

[22]  B. Kumar,et al.  Structural investigations of anthranilimide derivatives by CoMFA and CoMSIA 3D-QSAR studies reveal novel insight into their structures toward glycogen phosphorylase inhibition , 2011, SAR and QSAR in environmental research.

[23]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[24]  R. Cramer,et al.  Validation of the general purpose tripos 5.2 force field , 1989 .

[25]  W. Washburn.  Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. , 2009, Journal of medicinal chemistry.

[26]  W. Marsden.  I and J , 2012 .

[27]  Anshuman Dixit,et al.  An investigation of structurally diverse carbamates for acetylcholinesterase (AChE) inhibition using 3D-QSAR analysis. , 2008, Journal of molecular graphics & modelling.

[28]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[29]  Jinhwa Lee,et al.  Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners. , 2010, Bioorganic & medicinal chemistry.

[30]  Duane D. Miller,et al.  Recent and emerging anti‐diabetes targets , 2009, Medicinal research reviews.

[31]  R. Henry,et al.  SGLT2 inhibition — a novel strategy for diabetes treatment , 2010, Nature Reviews Drug Discovery.

[32]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[33]  Venkatesan Suryanarayanan,et al.  Atom-based 3D QSAR studies on novel N-β-d-xylosylindole derivatives as SGLT2 inhibitors , 2012, Medicinal Chemistry Research.

[34]  O. Marsenic.  Glucose control by the kidney: an emerging target in diabetes. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  N. Lewis,et al.  Phlorizin: a review , 2005, Diabetes/metabolism research and reviews.

[36]  Lalitha Guruprasad,et al.  Structural Insights into the Active Site of Human Sodium Dependent Glucose Co-Transporter 2: Homology Modelling, Molecular Docking, and 3D-QSAR Studies , 2012 .

[37]  G. Roglić,et al.  Mortality attributable to diabetes: estimates for the year 2010. , 2010, Diabetes research and clinical practice.